Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Kohei Shitara(National Cancer Center Hospital East), Florian Lordick(Leipzig University), Yung‐Jue Bang(Seoul National University), Peter C. Enzinger(Dana-Farber Cancer Institute), David H. Ilson(Memorial Sloan Kettering Cancer Center), Manish A. Shah(Cornell University), Eric Van Cutsem(KU Leuven), Rui‐Hua Xu(Sun Yat-sen University), Giuseppe Aprile(Azienda ULSS 9 TREVISO), Jianming Xu(Chinese PLA General Hospital), Joseph Chao(City of Hope), Roberto Pazo-Cid(Hospital Universitario Miguel Servet), Yoon‐Koo Kang(University of Ulsan), Jianning Yang(Astellas Pharma (United States)), Diarmuid Moran(Astellas Pharma (United States)), Pranob Bhattacharya(Astellas Pharma (United States)), Ahsan M. Arozullah(Astellas Pharma (United States)), Jung Wook Park(Astellas Pharma (United States)), Mok Oh(Astellas Pharma (United States)), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center)
Cited by 690
Abstract
Related Papers
No related papers found
Powered by citation graph analysis